SenzaGen (SENZA.ST)

Executive Summary

SenzaGen is a Swedish biotechnology company that has developed the GARD® (Genomic Allergen Rapid Detection) platform, a cutting-edge in vitro testing solution for skin sensitization. Leveraging genomics and machine learning, GARDskin is compliant with OECD guidelines 442E and 497, offering a reliable, animal-free alternative for regulatory toxicity assessments. The company serves the cosmetics, chemicals, and medical device industries, positioning itself as a key player in the global shift towards non-animal testing methods. With a strong IP portfolio and a validated commercial product, SenzaGen has established a foothold in a market driven by stringent regulations and growing ethical concerns. SenzaGen’s financial trajectory reflects its commercial momentum, with a market valuation of approximately SEK 180 million. The company continues to expand its GARD platform, aiming to cover additional toxicological endpoints and secure broader regulatory acceptance. As the demand for humane and accurate testing grows, SenzaGen is well-positioned to capture market share. Key upcoming catalysts include potential new product launches, strategic partnerships, and further regulatory endorsements that could accelerate adoption. The company’s focus on innovation and compliance underpins its long-term growth prospects in the evolving landscape of toxicity testing.

Upcoming Catalysts (preview)

• Q4 2026Launch of GARDpotency or new GARD-based assay70% success
• Q2 2027Major partnership with a top-tier cosmetics or chemical company55% success
• Q1 2027Achievement of profitability or positive cash flow milestone60% success